Ranibizumab

Generic Name
Ranibizumab
Brand Names
Byooviz, Cimerli, Lucentis, Susvimo, Ranivisio, Rimmyrah, Ximluci
Drug Type
Biotech
Chemical Formula
-
CAS Number
347396-82-1
Unique Ingredient Identifier
ZL1R02VT79
Background

Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against human vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology of age-related macular degeneration. Ranibizumab is used to treat various ocular disorders with abnormal growth of blood vessels, such as neovasc...

Indication

Ranibizumab injection for intravitreal use is indicated to treat Neovascular (wet) Age-related Macular Degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.
...

Associated Conditions
Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema, Myopic Choroidal Neovascularization, Neovascular Age-Related Macular Degeneration (nAMD)
Associated Therapies
-
Clinical Trials
Related News

Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

First Posted Date
2015-06-04
Last Posted Date
2020-07-30
Lead Sponsor
Allergan
Target Recruit Count
949
Registration Number
NCT02462486
Locations
🇺🇸

Paducah Retinal Center, Paducah, Kentucky, United States

🇺🇸

Maculacare - New York, New York, New York, United States

🇺🇸

Retina Vitreous Surgeons of Central NY, PC, Syracuse, New York, United States

and more 184 locations

A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

First Posted Date
2015-06-04
Last Posted Date
2020-07-28
Lead Sponsor
Allergan
Target Recruit Count
939
Registration Number
NCT02462928
Locations
🇨🇱

Instituto Oftalmologica Profesor Arentsen, Santiago, Región Metropolitana, Chile

🇵🇭

Asian Eye Institute, Makati City, Metro Manila, Philippines

🇵🇭

St. Luke's Medical Center, Quezon City, Metro Manila, Philippines

and more 148 locations

25-G Vitrectomy With Ranibizumab or Triamcinolone Acetonide on PDR in China-Randomized Clinical Trial

First Posted Date
2015-05-18
Last Posted Date
2018-09-24
Lead Sponsor
JUNYAN ZHANG
Target Recruit Count
200
Registration Number
NCT02447185
Locations
🇨🇳

The First People Hospital of Xuzhou, Xuzhou, Jiangsu, China

A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)

First Posted Date
2015-03-13
Last Posted Date
2024-10-30
Lead Sponsor
Ophthotech Corporation
Target Recruit Count
63
Registration Number
NCT02387957

RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity

First Posted Date
2015-03-03
Last Posted Date
2018-11-14
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
224
Registration Number
NCT02375971
Locations
🇬🇧

Novartis Investigative Site, Portsmouth, United Kingdom

Geographic Atrophy and Intravitreal Ranibizumab Injections

First Posted Date
2015-02-26
Last Posted Date
2015-02-26
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
90
Registration Number
NCT02372916
Locations
🇨🇦

Toronto Western Hospital, Toronto, Ontario, Canada

Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study

Phase 2
Completed
Conditions
Pterygium
Interventions
Drug: ranibizumab
First Posted Date
2015-01-19
Last Posted Date
2015-01-19
Lead Sponsor
Universiti Sains Malaysia
Target Recruit Count
36
Registration Number
NCT02342392

Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration

First Posted Date
2014-12-31
Last Posted Date
2014-12-31
Lead Sponsor
Mie University
Target Recruit Count
50
Registration Number
NCT02328209
Locations
🇯🇵

Mie University Graduate School of Medicine, Tsu, Japan

Change Oxygen Consumption Following Intravitreal Treatment of Lucentis (Ranibizumab) in Eyes With Diabetic Macular Edema

Completed
Conditions
Diabetic Macular Edema
First Posted Date
2014-12-31
Last Posted Date
2018-03-08
Lead Sponsor
Kagawa University
Target Recruit Count
30
Registration Number
NCT02329132
Locations
🇯🇵

Kagawa University Faculty of Medicine, Miki, Kagawa, Japan

25-Gauge Vitrectomy With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in China

First Posted Date
2014-12-31
Last Posted Date
2016-08-25
Lead Sponsor
JUNYAN ZHANG
Target Recruit Count
120
Registration Number
NCT02328118
Locations
🇨🇳

The First People Hospital of Xuzhou, Xuzhou, Jiangsu, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy